You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company said that dried blood-spot sampling improves access to HIV diagnostic testing and care, particularly among HIV-infected people living in remote areas.
The test provides healthcare professionals with a single result to confirm HIV diagnosis and differentiate HIV-1 and HIV-2, enabling appropriate treatment options.
The company said it is developing a rapid COVID-19 antibody test that will provide results in 12 minutes using a finger prick of blood.
The firm said declines across most business areas were slightly offset by increases in sales of sample collection devices.
The PCR test detects HIV-1 RNA on the NeuMoDx 96/288 Molecular Systems and joins the company's other bloodborne viral tests for hepatitis B and C.
UrSure is developing and commercializing products that measure adherence to HIV medications, including pre-exposure prophylaxis, or PrEP.
The DeepChek-HIV assays are designed for settings running either Sanger sequencing or next-generation sequencing workflows, according to the company.
The system is approved for use with the Procleix Ultrio Elite Assay, the Procleix WNV Assay, Procleix Zika Virus Assay, and the Procelix Babesia Assay.
The firm said international sales of its OraQuick HIV products increased 74 percent year over year, driven by sales of its OraQuick HIV Self-Test.
The platform can detect a single virus in more than 1,000 samples at a time or more than 160 viruses, including SARS-CoV-2, in a small number of samples.